Medical - Instruments & Supplies
Build Your Comparison
Side-by-side financial analysisStock Comparison
NYXH vs LIVN vs NVCR vs GKOS vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
Beverages - Non-Alcoholic
NYXH vs LIVN vs NVCR vs GKOS vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Beverages - Non-Alcoholic |
| Market Cap | $52M | $4.36B | $2.02B | $7.42B | $355.61B |
| Revenue (TTM) | $16M | $1.43B | $674M | $551M | $49.28B |
| Net Income (TTM) | $-86M | $107M | $-173M | $-189M | $13.70B |
| Gross Margin | 48.3% | 67.5% | 75.2% | 78.1% | 61.7% |
| Operating Margin | -5.3% | 13.4% | -27.2% | -15.6% | 29.3% |
| Forward P/E | — | 18.7x | — | — | 25.3x |
| Total Debt | $42M | $473M | $290M | $140M | $45.49B |
| Cash & Equiv. | $30M | $636M | $103M | $91M | $10.27B |
NYXH vs LIVN vs NVCR vs GKOS vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | Jun 26 | Return |
|---|---|---|---|
| Nyxoah S.A. (NYXH) | 100 | 5.8 | -94.2% |
| LivaNova PLC (LIVN) | 100 | 93.5 | -6.5% |
| NovoCure Limited (NVCR) | 100 | 8.7 | -91.3% |
| Glaukos Corporation (GKOS) | 100 | 134.7 | +34.7% |
| The Coca-Cola Compa… (KO) | 100 | 153.1 | +53.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NYXH vs LIVN vs NVCR vs GKOS vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NYXH ranks third and is worth considering specifically for growth exposure.
- Rev growth 121.6%, EPS growth -30.9%, 3Y rev CAGR 48.1%
- 121.6% revenue growth vs KO's 1.9%
LIVN is the #2 pick in this set and the best alternative if value and momentum is your priority.
- Lower P/E (18.7x vs 25.3x)
- +70.3% vs NYXH's -81.6%
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
GKOS is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.01
- 379.3% 10Y total return vs KO's 121.1%
- Lower volatility, beta 1.01, Low D/E 21.3%, current ratio 4.69x
- Beta 1.01, current ratio 4.69x
KO carries the broadest edge in this set and is the clearest fit for quality and dividends.
- 27.8% margin vs NYXH's -5.3%
- 2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend
- 13.1% ROA vs NYXH's -80.8%, ROIC 15.8% vs -76.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 121.6% revenue growth vs KO's 1.9% | |
| Value | Lower P/E (18.7x vs 25.3x) | |
| Quality / Margins | 27.8% margin vs NYXH's -5.3% | |
| Stability / Safety | Beta 1.01 vs NVCR's 2.21, lower leverage | |
| Dividends | 2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +70.3% vs NYXH's -81.6% | |
| Efficiency (ROA) | 13.1% ROA vs NYXH's -80.8%, ROIC 15.8% vs -76.4% |
NYXH vs LIVN vs NVCR vs GKOS vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
NYXH vs LIVN vs NVCR vs GKOS vs KO — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
KO leads in 2 of 6 categories
LIVN leads 1 • GKOS leads 1 • NYXH leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
KO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO is the larger business by revenue, generating $49.3B annually — 3020.2x NYXH's $16M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to NYXH's -5.3%. On growth, NYXH holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $16M | $1.4B | $674M | $551M | $49.3B |
| EBITDAEarnings before interest/tax | -$81M | $220M | -$165M | -$40M | $15.5B |
| Net IncomeAfter-tax profit | -$86M | $107M | -$173M | -$189M | $13.7B |
| Free Cash FlowCash after capex | -$73M | $161M | -$48M | -$18M | $12.6B |
| Gross MarginGross profit ÷ Revenue | +48.3% | +67.5% | +75.2% | +78.1% | +61.7% |
| Operating MarginEBIT ÷ Revenue | -5.3% | +13.4% | -27.2% | -15.6% | +29.3% |
| Net MarginNet income ÷ Revenue | -5.3% | +7.5% | -25.7% | -34.3% | +27.8% |
| FCF MarginFCF ÷ Revenue | -4.5% | +11.2% | -7.1% | -3.4% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.9% | +14.3% | +12.3% | +41.2% | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.3% | +106.7% | -100.0% | -6.3% | +18.2% |
Valuation Metrics
LIVN leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, LIVN's 17.4x EV/EBITDA is more attractive than KO's 26.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $52M | $4.4B | $2.0B | $7.4B | $355.6B |
| Enterprise ValueMkt cap + debt − cash | $66M | $4.2B | $2.2B | $7.5B | $390.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.51x | -17.84x | -14.57x | -38.66x | 27.18x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 18.68x | — | — | 25.27x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 2.43x |
| EV / EBITDAEnterprise value multiple | — | 17.39x | — | — | 26.39x |
| Price / SalesMarket cap ÷ Revenue | 4.48x | 3.14x | 3.09x | 14.63x | 7.42x |
| Price / BookPrice ÷ Book value/share | 0.93x | 3.61x | 5.82x | 11.05x | 10.40x |
| Price / FCFMarket cap ÷ FCF | — | 25.18x | — | — | 67.15x |
Profitability & Efficiency
KO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-164 for NYXH. GKOS carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs NYXH's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -164.4% | +9.1% | -50.8% | -26.5% | +41.1% |
| ROA (TTM)Return on assets | -80.8% | +4.2% | -16.5% | -20.1% | +13.1% |
| ROICReturn on invested capital | -76.4% | +11.5% | -16.4% | -9.2% | +15.8% |
| ROCEReturn on capital employed | -80.4% | +10.2% | -28.9% | -10.3% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 5 | 3 | 7 |
| Debt / EquityFinancial leverage | 0.86x | 0.39x | 0.85x | 0.21x | 1.33x |
| Net DebtTotal debt minus cash | $12M | -$162M | $187M | $49M | $35.2B |
| Cash & Equiv.Liquid assets | $30M | $636M | $103M | $91M | $10.3B |
| Total DebtShort + long-term debt | $42M | $473M | $290M | $140M | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | -32.73x | 5.18x | -96.80x | -18.69x | 10.70x |
Total Returns (Dividends Reinvested)
GKOS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $515 for NYXH. Over the past 12 months, LIVN leads with a +70.3% total return vs NYXH's -81.6%. The 3-year compound annual growth rate (CAGR) favors GKOS at 23.7% vs NYXH's -44.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -69.1% | +30.9% | +35.5% | +14.5% | +20.3% |
| 1-Year ReturnPast 12 months | -81.6% | +70.3% | -2.3% | +29.9% | +17.2% |
| 3-Year ReturnCumulative with dividends | -82.4% | +65.4% | -59.8% | +89.5% | +47.0% |
| 5-Year ReturnCumulative with dividends | -94.9% | -2.8% | -91.9% | +57.4% | +65.6% |
| 10-Year ReturnCumulative with dividends | -94.2% | +62.7% | +62.1% | +379.3% | +121.1% |
| CAGR (3Y)Annualised 3-year return | -44.0% | +18.3% | -26.2% | +23.7% | +13.7% |
Risk & Volatility
Evenly matched — LIVN and KO each lead in 1 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than NVCR's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.3% from its 52-week high vs NYXH's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.10x | 1.23x | 2.21x | 1.01x | -0.20x |
| 52-Week HighHighest price in past year | $8.59 | $80.73 | $18.92 | $148.11 | $84.04 |
| 52-Week LowLowest price in past year | $1.26 | $41.02 | $9.82 | $73.16 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +16.2% | +98.3% | +94.0% | +85.6% | +98.3% |
| RSI (14)Momentum oscillator 0–100 | 25.8 | 69.4 | 57.1 | 51.4 | 60.6 |
| Avg Volume (50D)Average daily shares traded | 189K | 727K | 1.5M | 859K | 12.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NYXH as "Buy", LIVN as "Buy", NVCR as "Buy", GKOS as "Buy", KO as "Buy". Consensus price targets imply 331.7% upside for NYXH (target: $6) vs -0.2% for LIVN (target: $79). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $6.00 | $79.25 | $33.50 | $149.00 | $86.13 |
| # AnalystsCovering analysts | 5 | 14 | 15 | 24 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +2.5% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 56 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% | 0.0% | 0.0% | +0.2% |
KO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). LIVN leads in 1 (Valuation Metrics). 1 tied.
NYXH vs LIVN vs NVCR vs GKOS vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NYXH or LIVN or NVCR or GKOS or KO a better buy right now?
For growth investors, Nyxoah S.
A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NYXH or LIVN or NVCR or GKOS or KO?
On forward P/E, LivaNova PLC is actually cheaper at 18.
7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — NYXH or LIVN or NVCR or GKOS or KO?
Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.
6%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: GKOS returned +379. 3% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NYXH or LIVN or NVCR or GKOS or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus NovoCure Limited's 2. 21β — meaning NVCR is approximately -1202% more volatile than KO relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.
05Which is growing faster — NYXH or LIVN or NVCR or GKOS or KO?
By revenue growth (latest reported year), Nyxoah S.
A. (NYXH) is pulling ahead at 121. 6% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NYXH or LIVN or NVCR or GKOS or KO?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NYXH or LIVN or NVCR or GKOS or KO more undervalued right now?
On forward earnings alone, LivaNova PLC (LIVN) trades at 18.
7x forward P/E versus 25. 3x for The Coca-Cola Company — 6. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.
08Which pays a better dividend — NYXH or LIVN or NVCR or GKOS or KO?
In this comparison, KO (2.
5% yield) pays a dividend. NYXH, LIVN, NVCR, GKOS do not pay a meaningful dividend and should not be held primarily for income.
09Is NYXH or LIVN or NVCR or GKOS or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +121. 1% 10Y return). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NYXH and LIVN and NVCR and GKOS and KO?
These companies operate in different sectors (NYXH (Healthcare) and LIVN (Healthcare) and NVCR (Healthcare) and GKOS (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NYXH is a small-cap high-growth stock; LIVN is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; KO is a large-cap quality compounder stock. KO pays a dividend while NYXH, LIVN, NVCR, GKOS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.